PNPT1
Basic information
Region (hg38): 2:55634061-55693863
Previous symbols: [ "DFNB70" ]
Links
Phenotypes
GenCC
Source:
- combined oxidative phosphorylation defect type 13 (Strong), mode of inheritance: AR
- autosomal recessive nonsyndromic hearing loss 70 (Limited), mode of inheritance: AR
- combined oxidative phosphorylation defect type 13 (Definitive), mode of inheritance: AR
- combined oxidative phosphorylation defect type 13 (Strong), mode of inheritance: AR
- hearing loss, autosomal recessive (Supportive), mode of inheritance: AR
- spinocerebellar ataxia type 25 (Limited), mode of inheritance: AD
- autosomal recessive nonsyndromic hearing loss 70 (Limited), mode of inheritance: Unknown
- combined oxidative phosphorylation defect type 13 (Strong), mode of inheritance: AR
- Leigh syndrome (Moderate), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Deafness, autosomal recessive 70, with or without adult-onset neurodegeneration | AR | Audiologic/Otolaryngologic | Early recognition and treatment of hearing impairment may improve outcomes, including speech and language development | Audiologic/Otolaryngologic; Biochemical; Neurologic | 23084290; 23084291; 30244537; 35411967 |
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (13 variants)
- Combined oxidative phosphorylation defect type 13 (3 variants)
- Autosomal recessive nonsyndromic hearing loss 70 (3 variants)
- Inborn genetic diseases (2 variants)
- PNPT1-related disorder (1 variants)
- Combined oxidative phosphorylation defect type 13;Autosomal recessive nonsyndromic hearing loss 70 (1 variants)
- Hereditary breast ovarian cancer syndrome (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the PNPT1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 123 | 130 | ||||
missense | 253 | 271 | ||||
nonsense | 11 | |||||
start loss | 0 | |||||
frameshift | 14 | |||||
inframe indel | 5 | |||||
splice donor/acceptor (+/-2bp) | 13 | 16 | ||||
splice region | 2 | 24 | 39 | 9 | 74 | |
non coding | 182 | 65 | 253 | |||
Total | 19 | 24 | 271 | 314 | 72 |
Highest pathogenic variant AF is 0.00000657
Variants in PNPT1
This is a list of pathogenic ClinVar variants found in the PNPT1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
2-55635931-TTCTA-T | Benign (Jun 14, 2018) | |||
2-55635975-CTA-C | Benign (Jun 26, 2018) | |||
2-55636078-A-T | Likely benign (Jul 08, 2018) | |||
2-55636166-A-G | Benign (Jul 27, 2018) | |||
2-55636225-T-TA | not specified • Combined oxidative phosphorylation defect type 13 • Autosomal recessive nonsyndromic hearing loss 70 | Benign (Oct 25, 2021) | ||
2-55636238-C-A | Uncertain significance (Dec 08, 2023) | |||
2-55636240-C-T | Likely benign (Sep 23, 2022) | |||
2-55636240-CT-C | Uncertain significance (Jul 12, 2022) | |||
2-55636244-G-C | Inborn genetic diseases | Uncertain significance (Nov 06, 2023) | ||
2-55636253-G-A | Uncertain significance (Aug 03, 2022) | |||
2-55636254-A-G | Uncertain significance (Aug 09, 2022) | |||
2-55636255-T-C | Likely benign (Nov 28, 2022) | |||
2-55636262-G-GAAAT | Uncertain significance (Mar 06, 2022) | |||
2-55636268-G-A | Uncertain significance (Jul 20, 2022) | |||
2-55636268-G-C | Uncertain significance (Feb 26, 2024) | |||
2-55636286-C-A | Uncertain significance (Oct 25, 2021) | |||
2-55636288-A-G | Likely benign (Mar 10, 2023) | |||
2-55636288-ACTT-A | Uncertain significance (Jun 28, 2022) | |||
2-55636296-C-T | Inborn genetic diseases | Uncertain significance (Jan 22, 2024) | ||
2-55636298-T-C | Uncertain significance (Nov 08, 2022) | |||
2-55636311-C-G | Uncertain significance (Jul 30, 2022) | |||
2-55636314-C-A | Uncertain significance (Jun 21, 2022) | |||
2-55636314-C-T | Uncertain significance (Mar 29, 2024) | |||
2-55636315-G-A | Likely benign (Dec 21, 2023) | |||
2-55636315-G-T | Likely benign (Dec 13, 2021) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
PNPT1 | protein_coding | protein_coding | ENST00000447944 | 28 | 59646 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.000401 | 1.00 | 125720 | 0 | 28 | 125748 | 0.000111 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.424 | 385 | 409 | 0.941 | 0.0000201 | 5029 |
Missense in Polyphen | 102 | 131 | 0.7786 | 1622 | ||
Synonymous | -1.18 | 164 | 146 | 1.12 | 0.00000785 | 1518 |
Loss of Function | 4.56 | 16 | 51.2 | 0.313 | 0.00000256 | 638 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000285 | 0.000277 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000165 | 0.000163 |
Finnish | 0.0000946 | 0.0000924 |
European (Non-Finnish) | 0.000126 | 0.000123 |
Middle Eastern | 0.000165 | 0.000163 |
South Asian | 0.0000665 | 0.0000653 |
Other | 0.000164 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: RNA-binding protein implicated in numerous RNA metabolic processes. Catalyzes the phosphorolysis of single-stranded polyribonucleotides processively in the 3'-to-5' direction. Mitochondrial intermembrane factor with RNA-processing exoribonulease activity. Component of the mitochondrial degradosome (mtEXO) complex, that degrades 3' overhang double- stranded RNA with a 3'-to-5' directionality in an ATP-dependent manner. Required for correct processing and polyadenylation of mitochondrial mRNAs. Plays a role as a cytoplasmic RNA import factor that mediates the translocation of small RNA components, like the 5S RNA, the RNA subunit of ribonuclease P and the mitochondrial RNA-processing (MRP) RNA, into the mitochondrial matrix. Plays a role in mitochondrial morphogenesis and respiration; regulates the expression of the electron transport chain (ETC) components at the mRNA and protein levels. In the cytoplasm, shows a 3'-to-5' exoribonuclease mediating mRNA degradation activity; degrades c-myc mRNA upon treatment with IFNB1/IFN-beta, resulting in a growth arrest in melanoma cells. Regulates the stability of specific mature miRNAs in melanoma cells; specifically and selectively degrades miR-221, preferentially. Plays also a role in RNA cell surveillance by cleaning up oxidized RNAs. Binds to the RNA subunit of ribonuclease P, MRP RNA and miR-221 microRNA. {ECO:0000269|PubMed:12473748, ECO:0000269|PubMed:12721301, ECO:0000269|PubMed:12798676, ECO:0000269|PubMed:16055741, ECO:0000269|PubMed:16410805, ECO:0000269|PubMed:16934922, ECO:0000269|PubMed:18083836, ECO:0000269|PubMed:18083837, ECO:0000269|PubMed:18501193, ECO:0000269|PubMed:19509288, ECO:0000269|PubMed:20547861, ECO:0000269|PubMed:20691904}.;
- Disease
- DISEASE: Combined oxidative phosphorylation deficiency 13 (COXPD13) [MIM:614932]: A mitochondrial disorder characterized by early onset severe encephalomyopathy, dystonia, choreoathetosis, bucofacial dyskinesias and combined mitochondrial respiratory chain deficiency. Nerve conductions velocities are decreased. Levels of plasma and cerebrospinal fluid lactate are increased. {ECO:0000269|PubMed:23084291}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Deafness, autosomal recessive, 70 (DFNB70) [MIM:614934]: A form of non-syndromic deafness characterized by severe, bilateral hearing impairment with prelingual onset, resulting in inability to acquire normal speech. {ECO:0000269|PubMed:23084290}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Pyrimidine metabolism - Homo sapiens (human);RNA degradation - Homo sapiens (human);Purine metabolism - Homo sapiens (human);Pyrimidine metabolism;Purine metabolism;Pyrimidine metabolism
(Consensus)
Recessive Scores
- pRec
- 0.0952
Intolerance Scores
- loftool
- 0.427
- rvis_EVS
- 0.14
- rvis_percentile_EVS
- 63.62
Haploinsufficiency Scores
- pHI
- 0.231
- hipred
- Y
- hipred_score
- 0.540
- ghis
- 0.562
Essentials
- essential_gene_CRISPR
- E
- essential_gene_CRISPR2
- E
- essential_gene_gene_trap
- E
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.915
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | High |
Cancer | High | Medium | High |
Mouse Genome Informatics
- Gene name
- Pnpt1
- Phenotype
- skeleton phenotype; hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; cellular phenotype;
Gene ontology
- Biological process
- mitochondrial RNA catabolic process;mitochondrial mRNA catabolic process;positive regulation of mitochondrial RNA catabolic process;mitochondrial RNA processing;mitochondrial RNA 5'-end processing;mitochondrial RNA 3'-end processing;RNA catabolic process;mRNA catabolic process;cellular response to oxidative stress;cellular response to interferon-beta;RNA import into mitochondrion;rRNA import into mitochondrion;regulation of cellular respiration;RNA polyadenylation;negative regulation of growth;protein homooligomerization;response to cAMP;response to growth hormone;positive regulation of mRNA catabolic process;protein homotrimerization;mitochondrion morphogenesis;nuclear polyadenylation-dependent mRNA catabolic process;mitotic cell cycle arrest;RNA phosphodiester bond hydrolysis, exonucleolytic;mitochondrial mRNA polyadenylation;liver regeneration;positive regulation of miRNA catabolic process;regulation of cellular senescence
- Cellular component
- nucleus;cytoplasm;mitochondrion;mitochondrial intermembrane space;endoplasmic reticulum membrane;cytosol;polysomal ribosome;mitochondrial degradosome
- Molecular function
- 3'-5'-exoribonuclease activity;RNA binding;polyribonucleotide nucleotidyltransferase activity;protein binding;poly(U) RNA binding;poly(G) binding;miRNA binding